Featured today by @MSKLibrary: First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab, in patients with advanced malignancies
dx.doi.org/10.1016/j.es...

#FAZ053 #PDL1 #ClinicalTrials #FirstInHuman